Cargando…

Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?

BACKGROUND: Cellular cholesterol efflux is a key step in reverse cholesterol transport that may impact on atherosclerotic cardiovascular risk. The process may be reliant on the availability of apolipoprotein (apo) B‐100‐containing lipoproteins to accept cholesterol from high‐density lipoprotein. Evo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ying, Qidi, Ronca, Annalisa, Chan, Dick C., Pang, Jing, Favari, Elda, Watts, Gerald F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541635/ https://www.ncbi.nlm.nih.gov/pubmed/35294778 http://dx.doi.org/10.1111/eci.13766

Ejemplares similares

Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure
por: Bigazzi, Federico, et al.
Publicado: (2017)

Cholesterol efflux capacity is increased in subjects with familial hypercholesterolemia in a retrospective case–control study
por: Sanz, Juana Maria, et al.
Publicado: (2023)

HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Di Costanzo, Alessia, et al.
Publicado: (2020)

Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects
por: Vuilleumier, Nicolas, et al.
Publicado: (2019)

Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
por: Choi, Seungbum, et al.
Publicado: (2013)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
por: Kutkiene, Sandra, et al.
Publicado: (2019)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Racial Differences in the Cholesterol-Lowering Effect of Statin
por: Naito, Ryo, et al.
Publicado: (2017)

Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes
por: Chamaria, Surbhi, et al.
Publicado: (2017)

RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin
por: Medina, Marisa W., et al.
Publicado: (2012)

Development and validation of novel automatable assay for cholesterol efflux capacity
por: Mutsuda, Yume, et al.
Publicado: (2023)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
por: Kamaruddin, Nurjannatul Naim, et al.
Publicado: (2021)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Statins redux: A re-assessment of how statins lower plasma cholesterol
por: Raghow, Rajendra
Publicado: (2017)

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma
por: Adorni, Maria Pia, et al.
Publicado: (2022)

Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance
por: Ward, Natalie C., et al.
Publicado: (2022)

Anti-Inflammatory Effects of Statins Beyond Cholesterol Lowering
por: Joo, Seung-Jae
Publicado: (2012)

Correction: RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin
por: Medina, Marisa W., et al.
Publicado: (2013)

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2018)

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Reverse Cholesterol Transport Pathway and Cholesterol Efflux in Diabetic Retinopathy
por: Zhang, Xinyuan, et al.
Publicado: (2021)

Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol
por: Berryman, Claire E, et al.
Publicado: (2017)

High Density Lipoprotein-Based Therapeutics: Novel Mechanism of Probucol in Foam Cells
por: Hafiane, Anouar, et al.
Publicado: (2022)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
por: Ying, Qidi, et al.
Publicado: (2021)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion
por: Chen, Xiao-Wei, et al.
Publicado: (2013)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

Association of Cholesterol Efflux Capacity With Clinical Features of Metabolic Syndrome: Relevance to Atherosclerosis
por: Gall, Julie, et al.
Publicado: (2016)

Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein
por: Schilcher, Irene, et al.
Publicado: (2017)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy
por: Kockx, Maaike, et al.
Publicado: (2022)

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
Publicado: (2023)

A meta-analysis of HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis
por: Xie, Binbin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bi3n7ar4aqefi5248na851lopg